Bioterrorism Threat Shines Spotlight on Drug Manufacturing

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

The recombinant vaccine, under the brand name Vimkunya, is recommended for persons age 12 and older who are traveling to a country or territory where there is a chikungunya outbreak.

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

Vitrakvi (larotrectinib) was first granted accelerated approval by FDA in November 2018.

Development of the state-of-the-art facility was made possible by a £2 million (US$2.6 million) round of funding, and a successful inspection by MHRA was completed in March 2025.